楊志云，首都醫(yī)科大學附屬北京地壇醫(yī)院中西醫(yī)結合中心主任醫(yī)師，教授，博導，科教處處長。北京市衛(wèi)生系統(tǒng)高層次人才，第六批全國老中醫(yī)藥專家學術經驗繼承人。從事中西醫(yī)結合肝病診療與研究20余年，在中西醫(yī)結合治療肝癌、肝硬化及并發(fā)癥、病毒性肝炎、脂肪性肝病等方面有豐富經驗。主要研究方向中西醫(yī)結合治療肝癌、肝硬化及并發(fā)癥、病毒性肝炎、脂肪性肝病等方面有豐富經驗。社會任職北京中西醫(yī)結合肝病學會秘書長中國醫(yī)師協(xié)會中西醫(yī)結合肝病學會常委獲獎榮譽省部級以上獎項3項科研成果近5年承擔國家及北京市自然基金3項。發(fā)表SCI論文18篇。授權發(fā)明專利1項。發(fā)表代表論文及著作：1.ZhiyunYang,LiWang,YixinHou,XianboWang.Effectsofmatrineonovalcell-mediatedliverregenerationandofRBP-JκandHES1[J].MolecularMedicineReports,2013,7(5):1533-15382.LinglingHe,XiaoliLiu,LijiaWang,ZhiyunYang.Thiazolidinedionesfornonalcoholicsteatohepatitis:Ameta-analysisofrandomizedclinicaltrials[J].Medicine,2016,95(42):e49473.XiaoliLiu,LinglingHe,JunyanHan,LijiaWang,MenggeLi,YuyongJiang,XianboWang,ZhiyunYang.Associationofneutrophil-lymphocyteratioandTlymphocyteswiththepathogenesisandprogressionofHBV-associatedprimarylivercancer[J].PLoSOne,2017,12(2):e01706054.LinglingHe,ShuanZhang,XiaoliLiu,YuyongJiang,XianboWang,ZhiyunYang.HbA1c-basedscoremodelforpredictingdeathriskinpatientswithHepatocellularCarcinomaandType2DiabetesMellitus[J].JournalofDiabetesResearch,2017,2017:38195025.LinglingHe,XiaoliLiu,YalinZhao,ShuanZhang,YuyongJiang,XianboWang,ZhiyunYang.Efficacyofnucleot(s)ideanalogstherapyinpatientswithunresectableHBV-relatedhepatocellularcarcinoma:asystematicreviewandmeta-analysis[J].DiseaseMarkers,2017,ID70759356.ShuanZhang,LinglingHe,XinhuiWang,ZhiboDang,XiaoliLiu,MenggeLi,XianboWang,ZhiyunYang,ANovelScoringmodelforpredictingmortalityriskinpatientswithcirrhosisandhepatorenalsyndrome[J].EuropeanJournalofGastroenterologyandHepatology,2018,30(8):938-943.7.XiaoliLiu,MenggeLi,XinhuiWang,ZhiboDang,YuyongJiang,XianboWang,ZhiyunYang.Effectofserumtriglyceridelevelontheprognosisofpatientswithhepatocellularcarcinomaintheabsenceofcirrhosis[J].Lipidsinhealthanddisease,2018,17(1):248.8.ZhiboDang,XiaoliLiu,MenggeLi,XinhuiWang,YuyongJiang,XianboWang,ZhiyunYang,ComparativeeffectivenessandsafetyoftraditionalChinesemedicinesupportingQiandenrichingbloodforcancerrelatedanemiainpatientsnotreceivingchemoradiotherapy:ameta-analysisandsystematicreview[J].DrugDesign,DevelopmentandTherapy,2019,13:221.9.LinglingHe,XiaoliLiu,ShuanZhang,MenggeLi,XianboWang,YuyongJiang,ZhiyunYang,Independentriskfactorsforpostoperative1-yearrecurrenceinpatientswithHBV-relatedhepatocellularcarcinoma≤3cm,GastroenterologyReport,accepted.10.XinhuiWang,XiaoliLiu,ZhiboDang,LihuaYu,YuyongJiang,XianboWang,ZhiyunYang*,Nucleos(t)ideanaloguesforreducinghepatocellularcarcinomainchronichepatitisBpatients:Asystematicreviewandmeta-analysis,GutandLiver,accepted.11.XiaoliLiu,MenggeLi,XinhuiWang,ZhiboDang,LihuaYu,XianboWang,YuyongJiang,ZhiyunYang*,EffectsofAdjuvantTraditionalChineseMedicineTherapyonLong-termSurvivalinPatientswithHepatocellularCarcinoma,Phytomedicine，accepted.承擔科研項目情況1.國家自然科學基金項目《苦參堿與肝卵圓細胞移植協(xié)同治療急性肝衰竭的實驗研究》（編號：30873423）。2.國家自然科學基金項目《養(yǎng)陰扶正解毒方逆轉T細胞功能耗竭治療乙肝相關原發(fā)性肝癌的機制研究》（編號：81874435）。3.北京市自然科學基金項目《WNT信號通路在慢性乙型肝炎肝纖維化進程中作用及涼血解毒方干預機制研究》（編號：7142081）。4.北京市科學技術委員會“首都臨床特色應用研究”重點項目《基于綜合預警模型篩選養(yǎng)陰扶正解毒法降低小肝癌微創(chuàng)術后復發(fā)率的優(yōu)勢人群臨床研究》（編號：Z171100001017082）。獲得專利及成果專利名稱:用CD8陽性的T細胞上PD-1和TIGIT確定HBV相關原發(fā)性肝癌預后的系統(tǒng)專利號：201711436077.3...擅長：中西醫(yī)結合肝病基礎與臨床研究（中西醫(yī)結合誘導肝干細胞分化修復肝損傷）。主治病種：各種急性病毒性肝炎、慢性乙型肝炎、慢性丙型肝炎、自身免疫性肝炎、藥物性肝炎、酒精性肝炎、脂肪肝、肝炎肝硬化、原發(fā)性肝癌等